Patrick Y. Lu

Patrick is the founder and has led Sirnaomics from an early discovery effort to an siRNA therapeutics product company, with multiple programs currently at clinical stage. Patrick brings 25+ years of nucleic acid drug development experience in Novartis, Digene and Intradigm which he was co-founder. He has led raising over $270 million for the company up to now and developing novel siRNA therapeutic, STP705, for treatment of cancer and fibrosis diseases. Patrick is also serving as Chairman of the Board of Directors of the Company.